Marco Confalonieri

Dr. Marco Confalonieri

Department of Pneumology and Respiratory Intermediate Care Unit, University Hospital of Cattinara, Trieste, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
Marco ConfalonieriMarco Confalonieri
Marco Confalonieri
RURosario Urbino
Rosario Urbino
APAlfredo Potena
Alfredo Potena
MPMarco Piattella
Marco Piattella
PPPiercarlo Parigi
Piercarlo Parigi
GMG. Umberto Meduri
G. Umberto Meduri
We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications. In a multicenter trial, patients admitted to the Intensive Care Unit (ICU) with severe community-acquired pneumonia received protocol-guided antibiotic treatment and were randomly assigned to hydrocortisone infusion or placebo. Hydrocortisone was given as an intravenous 200-mg bolus followed by infusion at a rate of 10 mg/hour for 7 days. Primary end-points of the study were improvement in PaO2:FIO2 (PaO2:FIO2 > 300 or ⩾ 100 increase from study entry) and multiple organ dysfunction syndrome (MODS) score by Study Day 8 and reduction in delayed septic shock. Forty-six patients entered the study. At study entry, the hydrocortisone group had lower PaO2:FIO2, and higher chest radiograph score and C-reactive protein level. By Study Day 8, treated patients had, compared with control subjects, a significant improvement in PaO2:FIO2 (p = 0.002) and chest radiograph score (p < 0.0001), and a significant reduction in C-reactive protein levels (p = 0.01), MODS score (p = 0.003), and delayed septic shock (p = 0.001). Hydrocortisone treatment was associated with a significant reduction in length of hospital stay (p = 0.03) and mortality (p = 0.009).

16 October 2001 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
MAM. Antonelli
M. Antonelli
GCG. Conti
G. Conti
MMM. Moro
M. Moro
AEA. Esquinas
A. Esquinas
GGG. Gonzalez-Diaz
G. Gonzalez-Diaz
GMG. Meduri
G. Meduri

10 June 2009 in JAMA
Verified
Journal Article
Closed access
PDF file
DADjillali Annane
Djillali Annane
EBEric Bellissant
Eric Bellissant
PBPierre-Edouard Bollaert
Pierre-Edouard Bollaert
JBJosef Briegel
Josef Briegel
Marco ConfalonieriMarco Confalonieri
Marco Confalonieri
GMG. Umberto Meduri
G. Umberto Meduri
Research from JAMA — Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults — A Systematic Review

1 November 1999 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
Marco ConfalonieriMarco Confalonieri
Marco Confalonieri
APAlfredo Potena
Alfredo Potena
GCGiorgio Carbone
Giorgio Carbone
RPRossana DELLA Porta
Rossana DELLA Porta
ETElizabeth A. Tolley
Elizabeth A. Tolley
GMG. Umberto Meduri
G. Umberto Meduri
In uncontrolled studies, noninvasive positive pressure ventilation (NPPV) was found useful in avoiding endotracheal intubation in patients with acute respiratory failure (ARF) caused by severe community-acquired pneumonia (CAP). We conducted a prospective, randomized study comparing standard treatment plus NPPV delivered through a face mask to standard treatment alone in patients with severe CAP and ARF. Patients fitting the American Thoracic Society criteria for severe CAP were included in presence of ARF (refractory hypoxemia and/or hypercapnia with acidosis). Exclusion criteria were: severe hemodynamic instability, requirement for emergent cardiopulmonary resuscitation, home mechanical ventilation or oxygen long-term supplementation, concomitant severe disease with a low expectation of life, inability to expectorate or contraindications to the use of the mask. Fifty-six consecutive patients (28 in each arm) were enrolled, and the two groups were similar at study entry. The use of NPPV was well tolerated, safe, and associated with a significant reduction in respiratory rate, need for endotracheal intubation (21% versus 50%; p = 0.03), and duration of intensive care unit (ICU) stay (1.8 ± 0.7 d versus 6 ± 1.8 d; p = 0.04). The two groups had a similar intensity of nursing care workload, time interval from study entry to endotracheal intubation, duration of hospitalization, and hospital mortality. Among patients with chronic obstructive pulmonary disease (COPD), those randomized to NPPV had a lower intensity of nursing care workload (p = 0.04) and improved 2-mo survival (88.9% versus 37.5%; p = 0.05). We conclude that in selected patients with ARF caused by severe CAP, NPPV was associated with a significant reduction in the rate of endotracheal intubation and duration of ICU stay. A 2-mo survival advantage was seen in patients with COPD. Confalonieri M, Potena A, Carbone G, Della Porta R, Tolley EA, Meduri GU. Acute respiratory failure in patients with severe community-acquired pneumonia: a prospective randomized evaluation of noninvasive ventilation.

1 February 2005 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
Marco ConfalonieriMarco Confalonieri
Marco Confalonieri
GGGiancarlo Garuti
Giancarlo Garuti
MCMaria Sofia Cattaruzza
Maria Sofia Cattaruzza
JOJ F Osborn
J F Osborn
MAM Antonelli
M Antonelli
IGItalian noninvasive positive pressure ventilation (NPPV) study group
Italian noninvasive positive pressure ventilation (NPPV) study group
Knowing the likelihood of failure of noninvasive positive pressure ventilation (NPPV) in patients with exacerbation of chronic obstructive pulmonary disease (COPD) could indicate the best choice between NPPV and endotracheal intubation instituted earlier. For this purpose, two risk charts were designed (at admission and after 2 h of NPPV) that included all relevant measurable clinical prognostic indicators derived from a population representing the patients seen routinely in clinical practice.Risk stratification of NPPV failure was assessed in 1,033 consecutive patients admitted to experienced hospital units, including two intensive care units, six respiratory intermediate care units, and five general wards. NPPV was successful in 797 patients.Patients with a Glasgow Coma Score <11, acute physiology and chronic health evaluation (APACHE) II ≥29, respiratory rate ≥30 breaths·min−1and pH at admission 70%. A pH 90%). The risk charts were validated on an independent group of 145 consecutive COPD patients treated with NPPV due to an acute ventilatory failure episode. To identify patients with a probability of failure >50%, the sensitivity and specificity were 33% and 96.7% on admission and 52.9% and 94.1% after 2 h of NPPV, respectively.The prediction chart, based on data from the current study, can function as a simple tool to predict the risk of failure of noninvasive positive pressure ventilation and thus improve clinical management of patients tailoring medical intervention.

Verified
Journal Article
Open access
PDF file
Barbara RuaroBarbara Ruaro
Barbara Ruaro
FSFrancesco Salton
Francesco Salton
LBLuca Braga
Luca Braga
BWBarbara Wade
Barbara Wade
PCPaola Confalonieri
Paola Confalonieri
Marco ConfalonieriMarco Confalonieri
Marco Confalonieri
Alveolar type II (ATII) cells are a key structure of the distal lung epithelium, where they exert their innate immune response and serve as progenitors of alveolar type I (ATI) cells, contributing to alveolar epithelial repair and regeneration. In the healthy lung, ATII cells coordinate the host defense mechanisms, not only generating a restrictive alveolar epithelial barrier, but also orchestrating host defense mechanisms and secreting surfactant proteins, which are important in lung protection against pathogen exposure. Moreover, surfactant proteins help to maintain homeostasis in the distal lung and reduce surface tension at the pulmonary air–liquid interface, thereby preventing atelectasis and reducing the work of breathing. ATII cells may also contribute to the fibroproliferative reaction by secreting growth factors and proinflammatory molecules after damage. Indeed, various acute and chronic diseases are associated with intensive inflammation. These include oedema, acute respiratory distress syndrome, fibrosis and numerous interstitial lung diseases, and are characterized by hyperplastic ATII cells which are considered an essential part of the epithelialization process and, consequently, wound healing. The aim of this review is that of revising the physiologic and pathologic role ATII cells play in pulmonary diseases, as, despite what has been learnt in the last few decades of research, the origin, phenotypic regulation and crosstalk of these cells still remain, in part, a mystery.